PERCEPTIVE ADVISORS LLC
Registered adviserFiling Date
Global Rank
#720
/ 8,818
▲ 120
Top Industry
Biotechnology
88.8%
Period ended 4 months ago
Filed Aug 14, 2026 · 2mo
26 quarters · since Mar 2020
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Holder type
Registered adviser
Form ADV roster, Oct 1, 2026
Regulatory AUM
$11,765,315,630
Main clients
Pooled investment vehicles
(99% of AUM)
Private funds
17 funds
· Mixed
Focus by fund count, roster of Oct 1, 2026
$11,655,707,855 gross assets
LEI
54930051M1DQYADROP30
Private funds on Schedule D 7.B.(1)
As filed Aug 8, 2024; SEC's bulk Form ADV archive ends with 2024 filings.
$9,576,438,337 gross assets in 20 funds
Hedge funds
$8,763,643,215
(5)
Venture capital funds
$687,043,502
(2)
Private equity funds
$114,792,308
(9)
Other private funds
$10,959,312
(4)
Form ADV history
Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Apr 2026 to Oct 2026 | $11,765,315,630 | Pooled investment vehicles (99%) |
| Mar 2026 | $8,459,663,000 | Pooled investment vehicles (99%) |
| May 2025 to Feb 2026 | $8,459,663,000 | Pooled investment vehicles (99%) |
| Apr 2025 | $8,459,663,000 | Pooled investment vehicles (99%) |
| Apr 2024 to Mar 2025 | $9,715,749,804 | Pooled investment vehicles (99%) |
| May 2023 to Mar 2024 | $9,508,525,129 | Pooled investment vehicles (98%) |
5 earlier changes not shown.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Style
Diversified active
Top 10 weight 49.0%, 28.3 effective positions, active share 96.1% against the Russell 2000 as of 2026-06-30; it meets none of the index-like, systematic-like or concentrated tests
Turnover
Medium turnover
38.0% over the last four quarters (30% to under 100%)
Horizon
Horizon unknown
The value-weighted holding period is at least 8.7 quarters, but 2.3% of the book was already held when coverage starts
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 96.1%; sector active share 90.8% against the combined 13F book's sector weights.
Over time 26 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
107 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
10.3%
−3.7 pts
Top 5
30.0%
−8.3 pts
Top 10
47.4%
−6.2 pts
HHI
333
Diversified−124
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.2% | $6,591,680,199 |
| Unclassified | 0.7% | $47,475,000 |
| Financial Services | 0.1% | $8,025,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | +4,355,046 | 14,106,187 | $263,926,758 | |
| BCRX | Biocryst Pharmaceuticals Inc | +2,874,855 | 10,308,888 | $103,088,880 | |
| TNGX | Tango Therapeutics, Inc. | +2,568,847 | 3,377,000 | $105,565,020 | |
| XFOR | X4 Pharmaceuticals, Inc | +1,195,843 | 7,933,491 | $37,049,402 | |
| EOLS | Evolus, Inc. | +1,172,423 | 2,459,285 | $17,067,437 | |
| ADPT | Adaptive Biotechnologies Corp | +1,064,825 | 1,217,325 | $26,111,621 | |
| DBVT | DBV Technologies S.A. | +688,959 | 1,653,350 | $27,114,940 | |
| ZYME | Zymeworks Inc. | +672,875 | 4,182,953 | $109,342,391 | |
| NRIX | Nurix Therapeutics, Inc. | +609,545 | 4,320,422 | $104,813,437 | |
| STRO | Sutro Biopharma, Inc. | +589,539 | 1,304,846 | $43,320,887 | |
| SYRE | Spyre Therapeutics, Inc. | +536,271 | 4,319,496 | $383,484,854 | |
| MGTX | MeiraGTx Holdings plc | +460,555 | 10,786,658 | $145,727,749 | |
| CRVS | Corvus Pharmaceuticals, Inc. | +375,000 | 2,667,441 | $39,851,568 | |
| CORT | Corcept Therapeutics Inc | +348,385 | 398,385 | $34,639,575 | |
| CTMX | CytomX Therapeutics, Inc. | +340,361 | 10,439,185 | $39,146,943 | |
| OCS | Oculis Holding AG | +315,000 | 808,827 | $11,218,430 | |
| SRZN | Surrozen, Inc. | +274,592 | 503,985 | $13,078,410 | |
| RVMD | Revolution Medicines, Inc. | +269,000 | 527,600 | $98,808,928 | |
| TENX | Tenax Therapeutics, Inc. | +252,218 | 1,700,000 | $24,735,000 | |
| SION | Sionna Therapeutics, Inc. | +246,561 | 905,000 | $39,810,950 | |
| RYTM | Rhythm Pharmaceuticals, Inc. | +212,500 | 2,586,295 | $287,156,333 | |
| SABS | SAB Biotherapeutics, Inc. | +195,758 | 6,627,501 | $25,847,253 | |
| IRTC | iRhythm Holdings, Inc. | +118,740 | 223,766 | $26,616,965 | |
| AORT | Artivion, Inc. | +100,000 | 1,737,290 | $39,036,906 | |
| RAPP | Rapport Therapeutics, Inc. | +99,419 | 773,342 | $32,225,161 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IVVD | Invivyd, Inc. | −2,368,667 | 18,490,636 | $16,123,834 | |
| DYN | Dyne Therapeutics, Inc. | −1,979,604 | 2,689,235 | $59,727,909 | |
| ENGN | enGene Therapeutics Inc. | −1,005,337 | 4,822,169 | $8,342,352 | |
| NAUT | Nautilus Biotechnology, Inc. | −960,000 | 11,634,211 | $21,755,974 | |
| VRDN | Viridian Therapeutics, Inc.\DE | −588,849 | 581,980 | $10,690,972 | |
| PALI | Palisade Bio, Inc. | −503,084 | 8,425,065 | $17,608,385 | |
| AXGN | Axogen, Inc. | −450,000 | 247,312 | $11,423,341 | |
| ANRO | Alto Neuroscience, Inc. | −400,000 | 1,609,893 | $42,485,076 | |
| PHAT | Phathom Pharmaceuticals, Inc. | −393,000 | 532,000 | $5,772,200 | |
| TVTX | Travere Therapeutics, Inc. | −389,977 | 3,752,574 | $213,183,728 | |
| ASND | Ascendis Pharma A/S | −367,700 | 1,163,721 | $310,387,665 | |
| ADMA | Adma Biologics, Inc. | −353,468 | 113,765 | $952,213 | |
| GH | Guardant Health, Inc. | −258,673 | 41,327 | $6,200,289 | |
| ABVX | Abivax S.A. | −254,884 | 74,000 | $9,861,240 | |
| PTGX | Protagonist Therapeutics, Inc | −249,000 | 981,879 | $120,358,727 | |
| IMVT | Immunovant, Inc. | −240,000 | 1,357,383 | $52,299,966 | |
| — | −232,271 | 1,308,113 | $173,625,838 | ||
| ROIV | Roivant Sciences Ltd. | −200,000 | 8,085,461 | $286,144,464 | |
| INBX | Inhibrx Biosciences, Inc. | −144,944 | 1,297,763 | $122,963,044 | |
| TWST | Twist Bioscience Corp | −113,188 | 36,812 | $3,787,218 | |
| CPIX | Cumberland Pharmaceuticals Inc | −99,996 | 96,982 | $628,443 | |
| ORKA | Oruka Therapeutics, Inc. | −50,438 | 1,345,063 | $128,009,645 | |
| EWTX | Edgewise Therapeutics, Inc. | −50,000 | 4,373,974 | $177,714,563 | |
| ISRG | Intuitive Surgical Inc | −33,535 | 51,884 | $20,633,229 | |
| RGEN | Repligen Corp | −32,329 | 248,212 | $33,866,045 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
21 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| KARD | Kardigan, Inc. | 8,200,662 | $195,585,788 | |
| AVLN | Avalyn Pharma Inc. | 2,675,296 | $88,070,744 | |
| BIIB | Biogen Inc. | 276,173 | $59,669,938 | |
| UNH | Unitedhealth Group Inc | 116,806 | $48,548,077 | |
| CRL | Charles River Laboratories International, Inc. | 140,000 | $31,750,600 | |
| DHR | Danaher Corp | 130,000 | $24,762,400 | |
| ANL | Adlai Nortye Group Ltd. | 1,793,190 | $20,621,685 | |
| NVCT | Nuvectis Pharma, Inc. | 1,000,000 | $18,390,000 | |
| MIRM | Mirum Pharmaceuticals, Inc. | 115,391 | $13,508,824 | |
| OSCR | Oscar Health, Inc. | 400,000 | $11,408,000 | |
| SPTX | Seaport Therapeutics, Inc. | 500,000 | $10,860,000 | |
| BSX | Boston Scientific Corp | 250,000 | $10,670,000 | |
| NTRA | Natera, Inc. | 34,689 | $9,416,329 | |
| RACC | Research Alliance Corp III | 750,000 | $8,025,000 | |
| CGEM | Cullinan Therapeutics, Inc. | 426,478 | $7,766,164 | |
| QURE | uniQure N.V. | 168,000 | $7,738,080 | |
| MOBI | Mobia Medical, Inc. | 523,654 | $7,016,963 | |
| OTLK | Outlook Therapeutics, Inc. | 3,139,216 | $4,991,353 | |
| XERS | Xeris Biopharma Holdings, Inc. | 467,013 | $3,698,742 | |
| BDSX | Biodesix Inc | 108,694 | $2,451,049 | |
| KPRX | Kiora Pharmaceuticals Inc | 438,471 | $1,153,178 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
11 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| DRUG | Bright Minds Biosciences Inc. | 377,544 | $27,549,385 | |
| BLTE | Belite Bio, Inc | 151,979 | $24,231,531 | |
| EVMN | Evommune, Inc. | 448,350 | $10,307,566 | |
| NMRA | Neumora Therapeutics, Inc. | 5,104,097 | $9,952,989 | |
| NBIX | Neurocrine Biosciences Inc | 65,050 | $8,569,687 | |
| IRD | Opus Genetics, Inc. | 1,835,842 | $8,353,081 | |
| IKT | Inhibikase Therapeutics, Inc. | 2,315,000 | $3,889,200 | |
| PTN | Palatin Technologies Inc | 61,945 | $1,079,081 | |
| CNTA | Centessa Pharmaceuticals plc | 5,258,903 | $0 | |
| — | 80,956 | $0 | ||
| — | 1,755,799 | $0 | ||
| No positions match the current search. | ||||
107 tracked positions ·
$6,647,180,199 total
· filing declares
109 positions · $6,661,817,069
· as of Jun 30, 2026
Showing 1–50
of 107 positions by value
· page 1 of 3
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PRAX |
Praxis Precision Medicines, Inc.
Healthcare
|
Held | 2,035,986 | $681,627,752 | 10.25% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
Added | 4,319,496 | $383,484,854 | 5.77% | |
| CELC |
Celcuity Inc.
Healthcare
|
Added | 3,197,200 | $334,491,064 | 5.03% | |
| ASND |
Ascendis Pharma A/S
Healthcare
|
Reduced | 1,163,721 | $310,387,665 | 4.67% | |
| RYTM |
Rhythm Pharmaceuticals, Inc.
Healthcare
|
Added | 2,586,295 | $287,156,333 | 4.32% | |
| ROIV |
Roivant Sciences Ltd.
Healthcare
|
Reduced | 8,085,461 | $286,144,464 | 4.30% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Added | 14,106,187 | $263,926,758 | 3.97% | |
| TVTX |
Travere Therapeutics, Inc.
Healthcare
|
Reduced | 3,752,574 | $213,183,728 | 3.21% | |
| KARD |
Kardigan, Inc.
Healthcare
|
NEW | 8,200,662 | $195,585,788 | 2.94% | |
|
|
Held | 1,580,505 | $195,192,368 | 2.94% | ||
| EWTX |
Edgewise Therapeutics, Inc.
Healthcare
|
Reduced | 4,373,974 | $177,714,563 | 2.67% | |
|
|
Reduced | 1,308,113 | $173,625,838 | 2.61% | ||
| AMLX |
Amylyx Pharmaceuticals, Inc.
Healthcare
|
Added | 8,334,882 | $149,694,480 | 2.25% | |
| MGTX |
MeiraGTx Holdings plc
Healthcare
|
Added | 10,786,658 | $145,727,749 | 2.19% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Reduced | 1,345,063 | $128,009,645 | 1.93% | |
| INBX |
Inhibrx Biosciences, Inc.
Healthcare
|
Reduced | 1,297,763 | $122,963,044 | 1.85% | |
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
Reduced | 981,879 | $120,358,727 | 1.81% | |
| SLDB |
Solid Biosciences Inc.
Healthcare
|
Held | 11,906,646 | $118,947,393 | 1.79% | |
| ZYME |
Zymeworks Inc.
Healthcare
|
Added | 4,182,953 | $109,342,391 | 1.64% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
Added | 3,377,000 | $105,565,020 | 1.59% | |
| IMTX |
Immatics N.V.
Healthcare
|
Held | 10,383,456 | $105,184,409 | 1.58% | |
| NRIX |
Nurix Therapeutics, Inc.
Healthcare
|
Added | 4,320,422 | $104,813,437 | 1.58% | |
| BCRX |
Biocryst Pharmaceuticals Inc
Healthcare
|
Added | 10,308,888 | $103,088,880 | 1.55% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Added | 527,600 | $98,808,928 | 1.49% | |
| AVLN |
Avalyn Pharma Inc.
Healthcare
|
NEW | 2,675,296 | $88,070,744 | 1.32% | |
| MRNA |
Moderna, Inc.
PUT
Healthcare
|
Held | 1,000,000 | $70,030,000 | 1.05% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Reduced | 2,689,235 | $59,727,909 | 0.90% | |
| BIIB |
Biogen Inc.
Healthcare
|
NEW | 276,173 | $59,669,938 | 0.90% | |
| IMVT |
Immunovant, Inc.
Healthcare
|
Reduced | 1,357,383 | $52,299,966 | 0.79% | |
| UNH |
Unitedhealth Group Inc
Healthcare
|
NEW | 116,806 | $48,548,077 | 0.73% | |
| XBI |
State Street(R) SPDR(R) S&P(R) Biotech ETF
PUT
|
NEW | 300,000 | $47,475,000 | 0.71% | |
| IONS |
Ionis Pharmaceuticals Inc
Healthcare
|
Added | 566,000 | $44,878,140 | 0.68% | |
| STRO |
Sutro Biopharma, Inc.
Healthcare
|
Added | 1,304,846 | $43,320,887 | 0.65% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Reduced | 1,609,893 | $42,485,076 | 0.64% | |
| JAZZ |
Jazz Pharmaceuticals plc
Healthcare
|
Held | 170,000 | $40,964,900 | 0.62% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
Added | 2,667,441 | $39,851,568 | 0.60% | |
| SION |
Sionna Therapeutics, Inc.
Healthcare
|
Added | 905,000 | $39,810,950 | 0.60% | |
| CTMX |
CytomX Therapeutics, Inc.
Healthcare
|
Added | 10,439,185 | $39,146,943 | 0.59% | |
| AORT |
Artivion, Inc.
Healthcare
|
Added | 1,737,290 | $39,036,906 | 0.59% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Added | 7,933,491 | $37,049,402 | 0.56% | |
| CAPR |
Capricor Therapeutics, Inc.
PUT
CALL
Healthcare
|
NEW | 1,500,000 | $36,120,000 | 0.54% | |
| CORT |
Corcept Therapeutics Inc
Healthcare
|
Added | 398,385 | $34,639,575 | 0.52% | |
| RGEN |
Repligen Corp
Healthcare
|
Reduced | 248,212 | $33,866,045 | 0.51% | |
| AVR |
Anteris Technologies Global Corp.
Healthcare
|
Held | 3,425,476 | $33,740,938 | 0.51% | |
| RAPP |
Rapport Therapeutics, Inc.
Healthcare
|
Added | 773,342 | $32,225,161 | 0.48% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
Held | 1,223,000 | $31,810,230 | 0.48% | |
| CRL |
Charles River Laboratories International, Inc.
Healthcare
|
NEW | 140,000 | $31,750,600 | 0.48% | |
| AXSM |
Axsome Therapeutics, Inc.
Healthcare
|
Reduced | 118,450 | $28,993,006 | 0.44% | |
| EYPT |
EyePoint, Inc.
PUT
Healthcare
|
NEW | 2,000,000 | $28,600,000 | 0.43% | |
| DBVT |
DBV Technologies S.A.
Healthcare
|
Added | 1,653,350 | $27,114,940 | 0.41% |
Showing the top 50 of 107 positions. Create a free account to see every position, past quarters, search, filters and CSV export.
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.